retatrutide parkinson disease clinical trial VisualAbstract: reduces body weight by 17.5% in patients with obesity New Phase 3 retatrutide data

CrossRef Circulating Estradiol as an Independent Risk Factor for Metabolic DysfunctionAssociated Steatotic Liver Disease and Fibrosis Risk in Women: Evidence From a Multicenter Health-Checkup Cohort Hyo Jung Cho, Seong Hee Kang, Hye Yeon Chon, SungA Bae, Eunju Kim, Seong Kyun Na, Su Jin Kim, Dooyeon Kim, Hye Ri Ahn, Huigyeong Kim, Jae Youn Cheong, Soon Koo Baik, Young Kul Jung, Soon Sun Kim, Hyung Joon Yim Journal of Korean Medical Science .2026;[Epub] CrossRef LY6D promotes hepatic steatosis via the GRB2AMPKSREBP1 signaling axis Qiurong Zhao, Linxin Chen, Sha Xie, Juanjuan Meng, Wei Cui, Yao Wu, Ting Zeng, Huaming Mou, Xiaohe Luo International Journal of Obesity .2026

Every protocol on the menu was chosen by a clinician

Previewing biopharma commercial, market access and development themes

We are so excited to be offering BPC-157 in clinic and can't wait to see what it can do for you and your loved ones

How do I get the best results from glutathione

Boll determines your eligibility for semaglutide injections